Related Experiment Video
Updated: May 20, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular
1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. adversity-makes-hero@goo.jp.
Abstract:
Lenvatinib, a multi-tyrosine kinase inhibitor approved for the treatment of multiple cancer types, can induce hypertension, which can be a prognostic indicator in patients with hepatocellular carcinoma. Further research into the mechanism of anticancer drug-induced blood pressure elevation is necessary and patients should be managed by a multi-disciplinary "Onco-Hypertension" team.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Targeted Cancer Therapies
There are several types of targeted therapies against...